Ambrx Enters $143.5 Million China Deal for Liver Cancer Treatment

Ambrx announced a $143.5 million agreement to in-license China rights for a liver cancer treatment with an anti-angiogenesis mechanism, developed by Tracon Pharma of San Diego . Two years ago, Ambrx, a San Diego-Shanghai antibody-conjugate biotech company, was acquired by Fosun Pharma (SHA: 600196; HK: 02196) and WuXi PharmaTech plus two China equity investors. The new agreement gives Ambrx rights to Tracon's proprietary endoglin antibody, TRC105 (carotuximab), in greater China . More details.... Stock Symbol: (NSDQ: TCON) Share this with colleagues: // //